Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| R35NS097273 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute of Neurological Disorders and Stroke (NINDS) | NIH |
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to measure, monitor, and analyze long term effects of SARS-CoV-2. The main purpose is to assess the post-hospitalization outcomes of patients who were diagnosed with SAR-CoV-2 by comparing to patients who were hospitalized with an acute neurological disease.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Non-COVID-19 Diagnosis Control Group | Subjects hospitalized and receiving intensive care for diagnosis of an acute neurological disease other than COVID-19 |
| |
| COVID-19 Diagnosis Case Group | Subjects previously hospitalized at Mayo Clinic Hospital for treatment of PCR test confirmed COVID-19 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| (R)-1-(2-chlorophenyl)- N-[11C] ([11C] PK11195) | Drug | Radiotracer used during the PET-MR scan of the study to identify signs of disease. Used in studies related to Alzheimer's disease. Only FDA approved for investigational use. |
| Measure | Description | Time Frame |
|---|---|---|
| Change in neurological, cognitive, and functional trajectories in participants who are status post hospitalization for COVID-19 and participants receiving intensive care for diagnosis other than COVID-19 | Collect participants' self reported response from questionnaire: Post-Covid Functional Status. | Baseline, 9 months, 12 months, 24 months. |
| Change in neurological, cognitive, and functional trajectories in participants who are status post hospitalization for COVID-19 and participants receiving intensive care for diagnosis other than COVID-19 | Collect participants' self reported response from questionnaire: Questionnaire for Verifying stroke-free Status. | Baseline, 9 months, 12 months, 24 months. |
| Change in neurological, cognitive, and functional trajectories in participants who are status post hospitalization for COVID-19 and participants receiving intensive care for diagnosis other than COVID-19 | Collect participants' self reported response from questionnaire: Patient Health Questionnaire. | Baseline, 9 months, 12 months, 24 months. |
| Change in neurological, cognitive, and functional trajectories in participants who are status post hospitalization for COVID-19 and participants receiving intensive care for diagnosis other than COVID-19 | Collect participants' self reported response from questionnaire: Six-Item Screener. | Baseline, 9 months, 12 months, 24 months. |
| Change in neurological, cognitive, and functional trajectories in participants who are status post hospitalization for COVID-19 and participants receiving intensive care for diagnosis other than COVID-19 | Collect participants' self reported response from questionnaire: Modified Rankin Scale. | Baseline, 9 months, 12 months, 24 months. |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
A sample size of 100 patients hospitalized for COVID-19 with a subset of control patients hospitalized and receiving intensive care for diagnosis other than COVID-19 or an acute neurological disease.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Young Erben, MD | Mayo Clinic | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Mayo Clinic Florida | Jacksonville | Florida | 32224 | United States |
Not provided
| Label | URL |
|---|---|
| Mayo Clinic Clinical Trials | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| C037850 | PK 11195 |
| C475519 | 2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 2-(4-[11C]methylamino phenyl)-6-hydroxybenzothiazole (11C]6-OH-BTA-1 or [11C]PIB) | Drug | Radiotracer used during the PET-MR scan of the study to identify signs of disease. Used in studies related to Alzheimer's disease. Only FDA approved for investigational use. |
|
| Change in neurological, cognitive, and functional trajectories in participants who are status post hospitalization for COVID-19 and participants receiving intensive care for diagnosis other than COVID-19 | Collect participants' self reported response from questionnaire: Clinical Dementia Rating. | Baseline, 9 months, 12 months, 24 months. |
| Change in neurological, cognitive, and functional trajectories in participants who are status post hospitalization for COVID-19 and participants receiving intensive care for diagnosis other than COVID-19 | Collect participants' self reported response from questionnaire: National Institutes of Health Stroke Scale. | Baseline, 9 months, 12 months, 24 months. |
| Change in neurological, cognitive, and functional trajectories in participants who are status post hospitalization for COVID-19 and participants receiving intensive care for diagnosis other than COVID-19 | Collect participants' self reported response from questionnaire: Neuropsychiatric Inventory Questionnaire. | Baseline, 9 months, 12 months, 24 months. |
| Change in neurological, cognitive, and functional trajectories in participants who are status post hospitalization for COVID-19 and participants receiving intensive care for diagnosis other than COVID-19 | Collect participants' self reported response from questionnaire: Epworth Sleepiness Scale. | Baseline, 9 months, 12 months, 24 months. |
| Change in neurological, cognitive, and functional trajectories in participants who are status post hospitalization for COVID-19 and participants receiving intensive care for diagnosis other than COVID-19 | Collect participants' self reported response from questionnaire: National Alzheimer's Coordinating Center Unified Data Set | Baseline, 9 months, 12 months, 24 months. |
| Change in neurological, cognitive, and functional trajectories in participants who are status post hospitalization for COVID-19 and participants receiving intensive care for diagnosis other than COVID-19 | Collect participants' self reported response from questionnaire: Unified Parkinson Disease Rating Scale III. | Baseline, 9 months, 12 months, 24 months. |
| Change in neurological, cognitive, and functional trajectories in participants who are status post hospitalization for COVID-19 and participants receiving intensive care for diagnosis other than COVID-19 | Collect participants' self reported response from questionnaire: Montreal Cognitive Assessment | Baseline, 9 months, 12 months, 24 months. |
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |